Back to top
more

AEterna Zentaris (AEZS)

(Delayed Data from NSDQ)

$8.37 USD

8.37
16,979

-0.02 (-0.24%)

Updated May 24, 2024 03:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for AEZS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

AEterna Zentaris Inc. [AEZS]

Reports for Purchase

Showing records 21 - 40 ( 168 total )

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

11/11/2019

Company Report

Pages: 6

Macrilen Commercialization Strategy Under Review

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for AEZS

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

08/15/2019

Company Report

Pages: 6

All Eyes on EU Out-Licensing of Macrilen; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

05/21/2019

Company Report

Pages: 6

An Uneventful Q1 With Development Activities to the Fore; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

01/17/2019

Company Report

Pages: 8

Macrilen Approved in the EU; What''s Next for Aeterna? Higher $5.50 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

11/14/2018

Company Report

Pages: 6

A Missed Opportunity in the US; European Approval Expected in 1H19; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

05/09/2018

Company Report

Pages: 6

Anticipating Macrilen''s Launch in the US and Approval in Europe; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

03/29/2018

Company Report

Pages: 6

Readying Macrilen for US Launch; Looking Ahead to EU Approval; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

11/29/2017

Company Report

Pages: 8

Potential Macrilen Approval Before Year End Could Attract Acquirers; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

07/05/2017

Daily Note

Pages: 4

Macrilen NDA Resubmitted; Potential Launch in 1Q18; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

05/10/2017

Company Report

Pages: 7

Focus on Macrilen With Potential Approval in 1Q18; Adjusting PT to $3.00; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

01/06/2017

Company Report

Pages: 7

Down But Not Out; Revised $7.50 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

11/16/2016

Company Report

Pages: 6

Macrilen and Zoptrex Phase 3 Study Results in 1Q17; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

08/11/2016

Company Report

Pages: 6

Looking Ahead to Two Pivotal Study Readouts; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

07/11/2016

Daily Note

Pages: 3

Two Major Calalysts in the Near Term; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

12/02/2015

Company Report

Pages: 6

Building an Oncology Franchise Ahead of Zoptrex; New PT $12.00; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

11/24/2015

Company Report

Pages: 6

Share Consolidation Complete; New PT $11; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

11/16/2015

Company Report

Pages: 7

Resolution of Warrant Overhang Removes Capital Structure Uncertainty; New $0.11 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

08/18/2015

Company Report

Pages: 5

Fundamentally Strong With Pressure From Capital Structure; Revising PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: AEterna Zentaris Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

07/28/2015

Daily Note

Pages: 3

Saizen Promotion Could Generate Better Economics; Reiterate Buy

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party